Blood test steers next move for lung cancer patients after standard therapy

This study looks at people with limited-stage small cell lung cancer whose disease is under control after chemoradiation. A special blood test (MRD) checks for leftover cancer signals. Those with positive results get a combination of immunotherapy and anti-angiogenic drugs to try to lower the risk of the cancer coming back. The goal is to see if this approach can turn the blood test negative and improve outcomes.